Core Viewpoint - Donaldson (DCI) reported a slight decline in revenue for the quarter ended January 2025, with earnings per share (EPS) showing a modest increase compared to the previous year [1] Financial Performance - Revenue for the quarter was 870million,down0.8908.65 million, resulting in a surprise of -4.25% [1] - EPS was reported at 0.83,anincreasefrom0.81 in the same quarter last year, but below the consensus estimate of 0.85,leadingtoanEPSsurpriseof−2.35253.70 million, below the estimated 277.26million,reflectingayear−over−yeardeclineof−3.7547.50 million, slightly below the estimated 555.49million,withayear−over−yearchangeof−0.568.80 million, surpassing the estimated 71.47million,markingayear−over−yearincreaseof+9.2207.50 million, below the estimate of 238.85million,representingayear−over−yeardeclineof−7.646.20 million, exceeding the estimate of 38.90million,withayear−over−yearincreaseof+18.880.20 million, below the estimate of 92.06million,reflectingayear−over−yeardeclineof−12.725.30 million, below the estimate of 29.49million,withayear−over−yeardeclineof−24.5442 million, exceeding the estimate of 431.17million,withayear−over−yearincreaseof+495.50 million, above the estimate of 93.47million[4]−IndustrialSolutionsreportedearningsbeforeincometaxesof40.90 million, below the estimate of 47.72million[4]−LifeSciencesreportedalossbeforeincometaxesof−0.50 million, better than the estimated loss of -1.22million[4]−Corporateandunallocatedreportedalossbeforeincometaxesof−10.90 million, slightly worse than the estimate of -$10.67 million [4] Stock Performance - Donaldson's shares returned -1.5% over the past month, compared to the Zacks S&P 500 composite's -2.2% change, indicating relative stability [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]